These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23676373)

  • 1. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality.
    Imamura T; Kinugawa K; Kato N; Minatsuki S; Muraoka H; Inaba T; Maki H; Shiga T; Hatano M; Hosoya Y; Takahashi M; Yao A; Kyo S; Ono M; Komuro I
    Int Heart J; 2013; 54(2):115-8. PubMed ID: 23676373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Shiga T; Hatano M; Yao A; Kyo S; Komuro I
    Circ J; 2013; 77(5):1208-13. PubMed ID: 23318562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan can improve clinical course in responders.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2013; 54(6):377-81. PubMed ID: 24309447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
    Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
    Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K; Doi K; Imamura T; Noiri E; Yahagi N; Nangaku M; Kinugawa K
    Nephrology (Carlton); 2015 Jun; 20(6):405-12. PubMed ID: 25619790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Renal Injury Induced by Hypersensitivity to Tolvaptan in an Elderly Patient with Congestive Heart Failure.
    Yamaguchi M; Nishihira K; Okubo T; Asada Y; Kitamura K
    Intern Med; 2015; 54(10):1243-6. PubMed ID: 25986264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study.
    Imamura T; Kinugawa K; Ohtani T; Sakata Y; Higo T; Kinugawa S; Tsutsui H; Sunagawa K; Komuro I
    Int Heart J; 2014; 55(3):264-7. PubMed ID: 24806383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
    Dohi K; Watanabe K; Ito M
    Circ J; 2013; 77(2):313-4. PubMed ID: 23269007
    [No Abstract]   [Full Text] [Related]  

  • 18. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
    Komiya S; Katsumata M; Ozawa M; Haze T; Kawano R; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
    Clin Exp Nephrol; 2022 Sep; 26(9):851-858. PubMed ID: 35471469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.